Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
FULC
Strong SellFulcrum Therapeutics, Inc. · Healthcare · United States · $294M · Avg Vol: $6M/d
COMPANY DESCRIPTION
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for genetically defined rare diseases. The company utilizes its proprietary product engine, FulcrumSeek, to identify drug targets that can regulate gene expression to treat diseases like sickle cell disease and facioscapulohumeral muscular dystrophy (FSHD). Its competitive advantage is anchored by its advanced computational biology platform and a pipeline of first-in-class therapeutic candidates.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.3M | 2.8M | 80.0M | 0 | 255.2% | — | — | — | — |
| EPS | -2.44 | -1.59 | -0.16 | -1.18 | — | -1.21 | -0.66 | -0.49 | — |
| Shares | 52.1M | 61.9M | 54.0M | 66.6M | +27.8% | 76.3M | — | — | — |
| Debt | 13.4M | 10.8M | 8.6M | 6.4M | -21.7% | 5.3M | — | — | — |
| Equity | 198.9M | 235.2M | 243.0M | 349.0M | 20.6% | — | — | — | — |
| Op CF | -97.0M | -91.0M | -2.2M | -60.1M | — | -65.8M | — | — | — |
| Inv CF | 12.4M | -36.7M | 32.2M | 30.7M | — | — | — | — | — |
| Fin CF | 84.3M | 118.1M | 2.7M | 168.7M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of FULC are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| FULC | Fulcrum Therapeutics, Inc.(you) | $294M | 19 | Strong Sell |
| OBIO | Orchestra BioMed Holdings, Inc. | $312M | 18 | Strong Sell |
| RNAC | Cartesian Therapeutics, Inc. | $290M | 17 | Strong Sell |
| ALXO | ALX Oncology Holdings Inc. | $277M | 21 | Sell |
| VNDA | Vanda Pharmaceuticals Inc. | $320M | 20 | Sell |
| FATE | Fate Therapeutics, Inc. | $291M | 22 | Sell |
| IMRX | Immuneering Corporation | $323M | 21 | Sell |
| SION | Sionna Therapeutics, Inc. | $265M | 17 | Strong Sell |
| IRD | Opus Genetics, Inc. | $307M | 15 | Strong Sell |
| PYXS | Pyxis Oncology, Inc. | $269M | 16 | Strong Sell |
Peer medians: ROE -25.6% · P/E 29.5x · Gross margin 58.8%